Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 199Breast Neoplasms 136Prostatic Neoplasms 72Neoplasms 62Neoplasm Metastasis 52Lung Neoplasms 45Stomach Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 22Squamous Cell Carcinoma of Head and Neck 17Ovarian Neoplasms 15Advanced Solid Tumors 14Recurrence 12Head and Neck Neoplasms 11Colorectal Neoplasms 11Carcinoma, Squamous Cell 11Urinary Bladder Neoplasms 10Melanoma 10Esophageal Neoplasms 10HER2-positive Breast Cancer 9Endometrial Neoplasms 9Carcinoma, Renal Cell 9Sarcoma 8Esophageal Squamous Cell Carcinoma 8Carcinoma, Transitional Cell 8Solid Tumor 7Prostatic Neoplasms, Castration-Resistant 7Pancreatic Neoplasms 7Carcinoma 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 6

Interventions

Gemcitabine 7Cisplatin 5pembrolizumab 4enfortumab vedotin 4Mitomycin 4Trastuzumab 3Pemetrexed 3Carboplatin 3dodecyl maltoside 2atezolizumab 2Sunitinib 2vinflunine 1valrubicin 1tucatinib 1palbociclib 1niraparib 1motexafin gadolinium 1cabozantinib 1avelumab 1apatorsen 1Water 1VMBP protocol 1Standard of Care 1Radiation Dose Hypofractionation 1Nivolumab 1Neoadjuvant Therapy 1Immunoglobulins, Intravenous 1Gels 1GSK-3326595 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Urologic Neoplasms × Docetaxel × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔